SynCore Biotechnology Co.,Ltd

TPEX:4192 Stock Report

Market Cap: NT$641.8m

SynCore BiotechnologyLtd Management

Management criteria checks 2/4

SynCore BiotechnologyLtd's CEO is Muh-Hwan Su, appointed in Jun 2013, has a tenure of 13.25 years. directly owns 0.082% of the company’s shares, worth NT$524.96K. The average tenure of the management team and the board of directors is 10.9 years and 12.8 years respectively.

Key information

Muh-Hwan Su

Chief executive officer

n/a

Total compensation

CEO salary percentagen/a
CEO tenure13.3yrs
CEO ownership0.08%
Management average tenure10.9yrs
Board average tenure12.8yrs

Recent management updates

Recent updates

Analysis Article • Mar 01

Health Check: How Prudently Does SynCore BiotechnologyLtd (GTSM:4192) Use Debt?

Warren Buffett famously said, 'Volatility is far from synonymous with risk.' It's only natural to consider a company's...

CEO Compensation Analysis

How has Muh-Hwan Su's remuneration changed compared to SynCore BiotechnologyLtd's earnings?
DateTotal CompensationSalaryCompany Earnings
Jun 30 2026n/an/a

-NT$47m

Mar 31 2026n/an/a

-NT$45m

Dec 31 2025n/an/a

-NT$46m

Sep 30 2025n/an/a

-NT$46m

Jun 30 2025n/an/a

-NT$53m

Mar 31 2025n/an/a

-NT$55m

Dec 31 2024n/an/a

-NT$54m

Sep 30 2024n/an/a

NT$364k

Jun 30 2024n/an/a

-NT$15m

Mar 31 2024n/an/a

-NT$28m

Dec 31 2023n/an/a

-NT$38m

Sep 30 2023n/an/a

-NT$162m

Jun 30 2023n/an/a

-NT$163m

Mar 31 2023n/an/a

-NT$170m

Dec 31 2022n/an/a

-NT$189m

Sep 30 2022n/an/a

-NT$187m

Jun 30 2022n/an/a

-NT$375m

Mar 31 2022n/an/a

-NT$429m

Dec 31 2021n/an/a

-NT$459m

Sep 30 2021n/an/a

-NT$481m

Jun 30 2021n/an/a

-NT$364m

Mar 31 2021n/an/a

-NT$386m

Dec 31 2020n/an/a

-NT$399m

Sep 30 2020n/an/a

-NT$409m

Jun 30 2020n/an/a

-NT$417m

Mar 31 2020n/an/a

-NT$430m

Dec 31 2019NT$4mNT$3m

-NT$409m

Compensation vs Market: Insufficient data to establish whether Muh-Hwan's total compensation is reasonable compared to companies of similar size in the TW market.

Compensation vs Earnings: Insufficient data to compare Muh-Hwan's compensation with company performance.

CEO

Muh-Hwan Su

13.3yrs
Tenure
NT$3,854,000
Compensation

Dr. Muh Hwan Su, Ph D, has been President of Syncore Biotechnology Co., Ltd. since June 03, 2013 and served as its Director since Jun 09, 2008 until April 24, 2018.Dr. Su serves as General Manager of SynC...

Leadership Team

NamePositionTenureCompensationOwnership
Muh-Hwan Su
President & GM13.3yrsNT$3.85m0.082%
NT$ 525.0k
Hui-Hung Wang
General Managerless than a yearNT$2.24mno data
Wen-Hsin Huang
VP & Head of Drug Development Department10.9yrsNT$1.49mno data
Chia-Hao Liang
Head of Financial & General Affairs Department and Accounting Manager13.3yrsno datano data
Ruey-Wen Lin
Head of Quality Assurance Department10.1yrsno datano data
10.9yrs
Average Tenure

Experienced Management: 4192's management team is seasoned and experienced (10.9 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Bo Lai
Director8.3yrsNT$138.00k0.44%
NT$ 2.8m
Yi-Ta Lee
Chairman18.3yrsNT$858.00k0.044%
NT$ 282.2k
Fu-Hsing Chang
Independent Director12.8yrsNT$187.00kno data
Hui-Hwa Yang
Director12.8yrsNT$138.00k0.41%
NT$ 2.6m
Whu-Ju Chu
Director13.3yrsNT$138.00kno data
Wen-Feng Chen
Independent Director12.8yrsNT$187.00kno data
Jih-Heng Li
Independent Director12.8yrsNT$187.00kno data
Shih-Chia Lin
Representative Director8.2yrsNT$145.00kno data
Cong Xian Lin
Independent Directorno datano datano data
Ming Zhu Chen
Independent Directorno datano datano data
12.8yrs
Average Tenure

Experienced Board: 4192's board of directors are seasoned and experienced ( 12.8 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/09/14 08:22
End of Day Share Price 2026/09/14 00:00
Earnings2026/06/30
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

SynCore Biotechnology Co.,Ltd is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.